TARO - Taro Pharmaceutical Industries Ltd.

NYSE - NYSE Delayed Price. Currency in USD

Taro Pharmaceutical Industries Ltd.

14 Hakitor Street
Haifa Bay
Haifa 2624761
972 4 847 5700

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees1,464

Key Executives

NameTitlePayExercisedYear Born
Mr. Uday V. BaldotaCEO & DirectorN/AN/A1970
Mr. Mariano BalaguerCFO, Chief Accounting Officer & VPN/AN/A1973
Mr. Itamar KarsentiVP & Head of Global OperationsN/AN/A1972
Mr. Itzik BaruchVP of Technical ServicesN/AN/A1963
Dr. Roman Kaplan Ph.D.VP of Scientific and Technical Compliance Mang.N/AN/A1947
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. It also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. The company offers its products primarily in the areas of topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, anti-inflammatory, and other therapeutic categories. The company distributes and sells its products directly to wholesalers, retail drug store chains, mass merchandisers, grocery chains, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.

Corporate Governance

Taro Pharmaceutical Industries Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.